methyl 4-(hydrazinylmethyl)benzoate | 870963-59-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-(hydrazinylmethyl)benzoate
• CAS: 870963-59-0
• 化学式: C₉H₁₂N₂O₂
• 分子量: 180.206
• InChiKey: NYFKLTVMDCXGJZ-UHFFFAOYSA-N

物化性质

• 沸点：
  355.4±35.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-(hydrazinylmethyl)benzoate 、 2-丙酰环己酮 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以12%的产率得到methyl 4-[(3-ethyl-4,5,6,7-tetrahydro-1H-indazol-1-yl)methyl]benzoate
  参考文献：
  名称：

  EP2269990

  摘要：

  公开号：

文献信息

• Pyrazole derivatives, compositions containing such compounds and methods of use
  申请人：Parmee R. Emma

  公开号：US20050272794A1

  公开（公告）日：2005-12-08

  Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

  揭示了附有萘基团的吡唑类化合物。这些化合物可用于治疗2型糖尿病及相关疾病。还包括药物组合物和治疗方法。
• PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS
  申请人：Packer Martin John

  公开号：US20090221663A1

  公开（公告）日：2009-09-03

  A compound of Formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  公式（I）的化合物及其药学上可接受的盐，其中可变基团在其内部定义；还描述了它们在抑制11βHSD1方面的用途，制造它们的过程以及包含它们的制药组合物。
• Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use
  申请人：Brockunier Linda

  公开号：US20080108620A1

  公开（公告）日：2008-05-08

  The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.

  本发明涉及取代吡唑，含有此类化合物的组合物以及治疗方法。这些化合物是胰高血糖素受体拮抗剂，因此可用于治疗、预防或延迟2型糖尿病的发生。
• HETEROCYCLIC COMPOUND
  申请人：Mochizuki Michiyo

  公开号：US20110118236A1

  公开（公告）日：2011-05-19

  An object of the present invention is to provide a novel AMPA receptor potentiator. A compound represented by the following formula (I) or a salt thereof: wherein in formula (I) R 1 represents (1) a halogen atom, or (2) cyano group, or the like; Ra and Rb each independently represent a hydrogen atom or C 1-4 alkyl; L represents a bond, or a spacer in which the number of atoms in the main chain is 1 to 8; Ring A represents (1) a non-aromatic carbon ring of 4-8 carbon atoms, or (2) a 4- to 8-membered non-aromatic heterocycle either of which is optionally substituted with 1 or more substituents selected from (a) halogen atoms, and (b) cyano group; and Ar represents a substituted phenyl group, or optionally substituted 5- or 6-membered aromatic heterocyclic group.

  本发明的目的是提供一种新型AMPA受体增强剂。化合物由以下式(I)或其盐所表示：其中在式(I)中，R1表示（1）卤素原子或（2）氰基等；Ra和Rb各自独立地表示氢原子或C1-4烷基；L表示键或主链中原子数为1至8的间隔物；环A表示（1）4-8个碳原子的非芳香碳环，或（2）4-至8个成员的非芳香杂环，其中任一环均可以选择性地用1个或多个取代基所取代，所述取代基选择自(a)卤素原子和(b)氰基；Ar表示取代苯基或可选择性取代的5-或6-成员芳香杂环基。
• Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors
  申请人：Packer Martin John

  公开号：US20110224273A1

  公开（公告）日：2011-09-15

  A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  化合物I的式子及其药用可接受的盐，其中变量基团在定义范围内；还描述了它们在抑制11βHSD1方面的使用，制造它们的过程以及包含它们的制药组合物。